Peptide aggregation: difference between revisions
Diff·revision 4 → 5·18:42, 5 Nov 2024
Difference between revision 4 and revision 5 of Peptide aggregation. 3 lines changed; the page grew by 446 bytes.
| Revision 4 — 05:15, 23 Oct 2024 RedirectRini (talk) convert the method-comparison paragraph to a table 2,241 bytes ±0 | Revision 5 — 18:42, 5 Nov 2024 Retention_Time_Rae (talk) give the limit of quantitation with the signal-to-noise ratio it assumes 2,687 bytes +446 | ||
|---|---|---|---|
| 15 | Nucleation-dependent aggregation, characteristic of amyloid formation, shows a lag phase during which nuclei form, followed by rapid growth. The lag is why a solution can appear stable for a period and then change quickly, and why seeding with pre-formed aggregate abolishes the lag entirely — a relevant consideration when material is drawn repeatedly from one container. | 15 | Nucleation-dependent aggregation, characteristic of amyloid formation, shows a lag phase during which nuclei form, followed by rapid growth. The lag is why a solution can appear stable for a period and then change quickly, and why seeding with pre-formed aggregate abolishes the lag entirely — a relevant consideration when material is drawn repeatedly from one container. |
| 16 | 16 | ||
| + | 17 | Interfacial aggregation is the mechanism most often encountered in handling. The air–liquid interface presents a hydrophobic surface at which peptides adsorb and unfold, so shaking a vial is substantially worse than swirling it. The same applies to repeated passage through a narrow needle.{{r|usp1503}} | |
| + | 18 | ||
| 17 | == References == | 19 | == References == |
| 18 | {{reflist}} | 20 | {{reflist}} |
| 19 | <ref name="manning2010">Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. "Stability of protein pharmaceuticals: an update." ''Pharmaceutical Research'' 27(4):544–575 (2010). DOI:10.1007/s11095-009-0045-6. PMID 20143256.</ref> | 21 | <ref name="manning2010">Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. "Stability of protein pharmaceuticals: an update." ''Pharmaceutical Research'' 27(4):544–575 (2010). DOI:10.1007/s11095-009-0045-6. PMID 20143256.</ref> |
| 20 | <ref name="westermark2011">Westermark P, Andersson A, Westermark GT. "Islet amyloid polypeptide, islet amyloid, and diabetes mellitus." ''Physiological Reviews'' 91(3):795–826 (2011). PMID 21742788.</ref> | 22 | <ref name="westermark2011">Westermark P, Andersson A, Westermark GT. "Islet amyloid polypeptide, islet amyloid, and diabetes mellitus." ''Physiological Reviews'' 91(3):795–826 (2011). PMID 21742788.</ref> |
| + | 23 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> | |
| 21 | 24 | ||
| 22 | {{DEFAULTSORT:Peptide aggregation}} | 25 | {{DEFAULTSORT:Peptide aggregation}} |